arrow
M

Manish C. Choudhary

Brigham and Women's Hospital
H指数:25
被引数:5,159

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expansion of stemlike HIV-specific CD8+ T cells and limited viral epitope diversity characterize durable posttreatment control of HIV

干性HIV特异性CD8+ T细胞的扩增和有限的病毒表位多样性是治疗后期持续控制HIV的特征

2026-04-220
PRE
Virologic characteristics of SARS-CoV-2 infection across evolving Omicron subvariants
2025-10-220
OA
Cross-Neutralization of Distant Coronaviruses Strongly Correlates with Spike S2-Specific Antibodies from Immunocompetent and Immunocompromised Vaccinated SARS-CoV-2-Infected Patients

远缘冠状病毒的交叉中和作用与免疫健全和免疫缺陷的SARS-CoV-2感染疫苗接种者中S2特异性抗体显著相关

2025-09-040
OA
Protracted SARS-CoV-2 Infection in B-cell Depleted Patients: Immunologic and Viral Characteristics and Response to Dual and Extended Antiviral Therapy

B细胞耗竭患者中慢性SARS-CoV-2感染:免疫学及病毒学特征以及对联合和延长抗病毒治疗的反应

2025-09-014
PRE
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearance
2025-02-040
OAAI
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

Tixagevimab/cilgavimab 或安慰剂用于 ACTIV-2 研究:安全性、药代动力学及中和抗体和抗药抗体

2025-02-010
OAAI
SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency
2024-01-2427
OA
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy An Observational Study
2023-12-0128
OA
Variant-Specific Viral Kinetics in Acute COVID-19

急性新型冠状病毒肺炎的变异特异性病毒动力学

2023-08-311
OA
Safety and Efficacy of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies Amubarvimab Plus Romlusevimab in Nonhospitalized Patients With COVID-19
2023-05-0122
OA
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19 (vol 13, 4931, 2022)
2023-01-191
OAAI
Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant
2022-10-1011
OA
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19
2022-08-2236
OAAI
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) Infection
2022-07-21112
OAAI
Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19)

尼马曲韦-利托那韦治疗冠状病毒疾病2019 (新型冠状病毒肺炎) 后的病毒学反弹特征

2022-07-1574
OA
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection
2022-07-0110
OAAI